Research outputs in respiratory medicine

Rippon, I.; Lewison, G.; Partridge, M. R.
January 2005
Thorax;Jan2005, Vol. 60 Issue 1, p63
Academic Journal
Background: There is currently little information regarding how much the distribution of research activity in respiratory medicine reflects the interests of its clinicians and scientists, the disease burden in any country, or the availability of funding. Methods: A total of 81 419 respiratory medicine publications identified in the Science Citation Index for the years 1996-2001 were assigned to 14 subject areas (mainly based on title words) and to 15 OECD countries. Outputs were compared with a nation's disease burdens and, for the UK, the sources of research funding were investigated. Results and conclusions: Overall, Finland, Canada, Spain and the UK had the greatest relative commitment to respiratory medicine research expressed as a ratio of their share of world biomedical research. The largest subject areas were asthma, lung cancer, and paediatric lung disease, each with over 1400 papers published per year. Australia and Canada led in relative commitment to sleep research and Sweden and Finland led in research on asthma. Australia and the UK produced significant numbers of publications on cystic fibrosis (CF) but Finland produced few. The Netherlands has a strong output on chronic obstructive pulmonary disease (COPD), France and the UK on diffuse parenchymal lung disease (DPLD), and Finland dominated occupational lung disease research but had few publications on HIV/AIDS where Spain proportionately produced most. Finland and Australia had strong outputs in paediatric lung disease research. For most subject areas the research output of a country correlated poorly with disease burden. In the UK, lung cancer research appeared unduly low in relation to the number of deaths and COPD outputs were low compared with those for asthma. However, correlations were positive for the burden of CF and pulmonary complications of HIV/AIDS which explains, for example, the low outputs in these subject areas from Finland. The strong performance in CF research in the UK is likely to reflect significant charitable funding, while sleep research, pulmonary circulatory disease, and DPLD had little stated external funding or sponsorship.


Related Articles

  • Airwaves.  // Thorax;Apr2010, Vol. 65 Issue 4, pi 

    An introduction is presented in which the editor discusses various reports within the issue on topics including cystic fibrosis (CF), non-invasive ventilation (NIV) for hypercapnic chronic obstructive pulmonary disease (COPD), and lung cancer.

  • NEW PRODUCTS.  // MPR - Physician Assistants' Edition;Winter2013/2014, Vol. 20 Issue 4, pA11 

    The article offers information on several generic products including Adasuve drug from Teva, Breo Ellipta drug from GlaxoSmithKline, and Fetzima drug from Forest.

  • Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery. Willis, Lauren; Hayes, Don; Mansour, Heidi // Lung;Jun2012, Vol. 190 Issue 3, p251 

    Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many...

  • Unravelling salt transport in cystic fibrosis. Noone, P. G.; Southern, K. W. // Thorax;Nov2004, Vol. 59 Issue 11, p916 

    This article presents information related to salt transport in cystic fibrosis (CF). CF is characterized by thick viscid air-way secretions, the development of progressive airways obstruction and bronchiectasis. In patients with CF, the magnitude of sodium absorption across airway epithelia and...

  • cystic fibrosis.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p567 

    An encyclopedia entry for "cystic fibrosis," is presented. Cystic fibrosis is an autosomal recessive disease that is potentially fatal. The disease can manifest itself in many body systems such as the lungs, the pancreas and the skeleton. It can cause chronic obstructive pulmonary disease,...

  • Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Hartl, Dominik; Latzin, Philipp; Hordijk, Peter; Marcos, Veronica; Rudolph, Carsten; Woischnik, Markus; Krauss-Etschmann, Susanne; Koller, Barbara; Reinhardt, Dietrich; Roscher, Adelbert A; Roos, Dirk; Griese, Matthias // Nature Medicine;Dec2007, Vol. 13 Issue 12, p1423 

    Interleukin-8 (IL-8) activates neutrophils via the chemokine receptors CXCR1 and CXCR2. However, the airways of individuals with cystic fibrosis are frequently colonized by bacterial pathogens, despite the presence of large numbers of neutrophils and IL-8. Here we show that IL-8 promotes...

  • Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Moskowitz, Samuel M.; Gibson, Ronald L.; Effmann, Eric L. // Pediatric Radiology;Aug2005, Vol. 35 Issue 8, p739 

    Cystic fibrosis (CF) is a multiorgan disease caused by mutation of the CF transmembrane conductance regulator (CFTR) gene. Obstructive lung disease is the predominant cause of morbidity and mortality; thus, most efforts to improve outcomes are directed toward slowing or halting lung-disease...

  • Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis. Oioo, J. C.; Mulrennan, S. A.; KasteIik, J. A.; Morice, A. H.; Redington, A. E. // Thorax;Jan2005, Vol. 60 Issue 1, p22 

    Background: It has been proposed that the ph of airway lining fluid may regulate the fractional exhaled concentration of nitric oxide (FENO) in respiratory disease. Methods: FENO, exhaled breath condensate (BC) ph, and BC concentrations of nitrite plus nitrate (NO2/NO3) were compared in 12...

  • New Test for Lung Disorder. Uehling, Mark D. // Bio-IT World;Aug2004, Vol. 3 Issue 8, p14 

    Reports on a project by Laboratory Corporation of America which aimed to develop a DNA test for the risk factor that leads to chronic obstructive pulmonary disease. Effect of &alpha[sub1[-antitrypsin deficiency (ATT); Significance of a cystic fibrosis test to the ATT project.


Read the Article


Sign out of this library

Other Topics